SPORANOX by Johnson & Johnson is mechanism of action in vitro studies have demonstrated that itraconazole inhibits the cytochrome p450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. Approved for the following fungal infections in immunocompromised, non-immunocompromised patients: blastomycosis, pulmonary and 11 more indications. First approved in 1997.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
SPORANOX (itraconazole) is an oral antifungal solution approved in 1997 that treats serious fungal infections including blastomycosis, histoplasmosis, and aspergillosis in immunocompromised and non-immunocompromised patients, as well as onychomycosis (nail fungus). It works by inhibiting cytochrome P450-dependent ergosterol synthesis, disrupting fungal cell membrane integrity.
Product approaching loss of exclusivity with minimal Part D utilization signals a contracting commercial footprint and reduced team investment.
Mechanism of Action In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.
Worked on SPORANOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moSPORANOX presents a challenging career environment with zero linked job openings and a product in LOE-approaching lifecycle stage. Working on this asset likely involves managing decline, cost containment, and transition planning rather than growth or innovation.